MA53665A - Agonistes du récepteur farnésoïde x et leurs utilisations - Google Patents
Agonistes du récepteur farnésoïde x et leurs utilisationsInfo
- Publication number
- MA53665A MA53665A MA053665A MA53665A MA53665A MA 53665 A MA53665 A MA 53665A MA 053665 A MA053665 A MA 053665A MA 53665 A MA53665 A MA 53665A MA 53665 A MA53665 A MA 53665A
- Authority
- MA
- Morocco
- Prior art keywords
- farnesoid
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862733006P | 2018-09-18 | 2018-09-18 | |
US201862733004P | 2018-09-18 | 2018-09-18 | |
US201962881560P | 2019-08-01 | 2019-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA53665A true MA53665A (fr) | 2021-07-28 |
Family
ID=69887982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053665A MA53665A (fr) | 2018-09-18 | 2019-09-17 | Agonistes du récepteur farnésoïde x et leurs utilisations |
Country Status (15)
Country | Link |
---|---|
US (3) | US11084817B2 (fr) |
EP (1) | EP3852748A4 (fr) |
JP (1) | JP2022500392A (fr) |
KR (1) | KR20210076910A (fr) |
CN (1) | CN113056271A (fr) |
AU (1) | AU2019344903A1 (fr) |
BR (1) | BR112021004919A2 (fr) |
CA (1) | CA3112411A1 (fr) |
CL (1) | CL2021000632A1 (fr) |
IL (1) | IL281475A (fr) |
MA (1) | MA53665A (fr) |
MX (1) | MX2021003110A (fr) |
PH (1) | PH12021550605A1 (fr) |
SG (1) | SG11202102651SA (fr) |
WO (1) | WO2020061113A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7174709B2 (ja) | 2017-03-15 | 2022-11-17 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
JP7258763B2 (ja) * | 2017-03-15 | 2023-04-17 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
JP2022500392A (ja) | 2018-09-18 | 2022-01-04 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
WO2021144330A1 (fr) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d'agonistes de fxr pour traiter une infection par le virus de l'hépatite d |
EP4121012A1 (fr) * | 2020-03-18 | 2023-01-25 | Metacrine, Inc. | Formulations d'un agoniste du récepteur farnésoïde x |
WO2021188692A1 (fr) * | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formes cristallines d'un agoniste du récepteur farnésoïde x |
AU2021240001A1 (en) * | 2020-03-18 | 2022-10-13 | Organovo, Inc. | Farnesoid X receptor agonists for the treatment of disease |
EP4277622A1 (fr) | 2021-01-14 | 2023-11-22 | ENYO Pharma | Effet synergique d'un agoniste de fxr et d'ifn pour le traitement d'une infection par le virus de l'hépatite b |
TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Enyo製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
CN116554121A (zh) * | 2023-05-05 | 2023-08-08 | 济南悟通生物科技有限公司 | 一种2-异丁基噻唑的合成方法 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1183229B1 (fr) | 1999-05-17 | 2005-10-26 | Novo Nordisk A/S | Antagonistes/agonistes inverses de glucagon |
CA2372887A1 (fr) | 1999-05-25 | 2000-11-30 | Sepracor Inc. | Composes heterocycliques analgesiques et procedes d'utilisation de ces derniers |
US6645980B1 (en) | 2000-05-25 | 2003-11-11 | Sepracor Inc. | Heterocyclic analgesic compounds and methods of use thereof |
US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
BR0113989A (pt) | 2000-09-25 | 2004-01-27 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, processo para a preparação de uma composição farmacêutica, e, uso de pelo menos um dos compostos |
FR2815032B1 (fr) | 2000-10-10 | 2003-08-08 | Pf Medicament | Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations |
FR2825706B1 (fr) | 2001-06-06 | 2003-12-12 | Pf Medicament | Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase |
FR2839974B1 (fr) | 2002-05-24 | 2004-07-16 | Pf Medicament | Derives de phenyl-furane ou de phenyl-thiophene,leur preparation et leur application a titre de medicament |
WO2004009549A2 (fr) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines utiles pour traiter des maladies du systeme nerveux central |
JP2006508061A (ja) | 2002-09-20 | 2006-03-09 | ファイザー・プロダクツ・インク | エストロゲン受容体に対するアミドおよびスルホンアミドリガンド |
WO2004046162A2 (fr) | 2002-11-14 | 2004-06-03 | The Scripps Research Institute | Agonistes fxr non steroidiques |
AU2003298654A1 (en) | 2002-11-15 | 2004-06-15 | The Salk Institute For Biological Studies | Structure of the farnesoid x receptor ligand binding domain and methods of use therefor |
US20050143449A1 (en) | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
US7335658B2 (en) | 2003-07-30 | 2008-02-26 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
US7754711B2 (en) | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
WO2005058822A1 (fr) | 2003-12-17 | 2005-06-30 | Actelion Pharmaceuticals Ltd | Cycloalcanes amines substitues |
US20050239751A1 (en) | 2004-03-26 | 2005-10-27 | Rigel Pharmaceuticals, Inc. | Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses |
US20050272784A1 (en) | 2004-05-07 | 2005-12-08 | Xiaobing Li | Inhibitors of bacterial Type III protein secretion systems |
JP2006199656A (ja) | 2005-01-24 | 2006-08-03 | Kowa Co | アミド基を有する環状アミン化合物 |
MY144229A (en) | 2006-01-26 | 2011-08-15 | Xenon Pharmaceuticals Inc | Pyridazine derivatives and their use as therapeutic agents |
KR20080098548A (ko) | 2006-03-28 | 2008-11-10 | 노파르티스 아게 | G 단백질 관련 질환의 치료를 위한 아미드 유도체 및 그의투여 |
US20080081824A1 (en) | 2006-09-29 | 2008-04-03 | Bristol-Myers Squibb Company | Substituted piperidines as modulators of chemokine receptor activity |
WO2008065500A2 (fr) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i |
WO2009076747A1 (fr) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Inhibiteurs de polymérase virale |
WO2010001869A1 (fr) | 2008-06-30 | 2010-01-07 | 武田薬品工業株式会社 | Composé de benzène tétrasubstitué et son utilisation |
JP2010077109A (ja) | 2008-08-28 | 2010-04-08 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
WO2011006935A2 (fr) | 2009-07-15 | 2011-01-20 | Merck Serono S.A. | Dérivés de tétrazole |
EP2454257B1 (fr) | 2009-07-15 | 2013-08-21 | AbbVie Inc. | Pyrrolopyridines inhibiteurs de kinases |
FR2963005B1 (fr) | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
SI2688403T1 (sl) | 2011-03-23 | 2017-08-31 | Trevena, Inc. | Ligandi opioidnih receptorjev in metode uporabe in izdelave istega |
EP2545964A1 (fr) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité |
JPWO2013008706A1 (ja) | 2011-07-13 | 2015-02-23 | エム・テクニック株式会社 | 結晶子径を制御された微粒子の製造方法 |
RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
GB201316824D0 (en) | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
KR20160132111A (ko) | 2014-03-13 | 2016-11-16 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Fxr 작용제와 제조방법 및 용도 |
EP3116851B1 (fr) | 2014-03-13 | 2023-07-26 | Salk Institute for Biological Studies | Analogues de la féxaramine et procédés de préparation et d'utilisation |
US20150258052A1 (en) | 2014-03-13 | 2015-09-17 | Salk Institute For Biological Studies | Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue |
US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
WO2016116054A1 (fr) | 2015-01-22 | 2016-07-28 | Xiamen University | Modulateurs du récepteur farnésoïde x et leurs méthodes d'utilisation |
WO2016149111A1 (fr) | 2015-03-13 | 2016-09-22 | Salk Institute For Biological Studies | Traitement de diabètes auto-immuns latents des adultes à agonistes de récepteur x farnésoïde pour activer les récepteurs intestinaux |
WO2017018751A1 (fr) | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Nouveau composé présentant une activité inhibitrice de blt et composition, destiné à prévenir ou à traiter des maladies inflammatoires, contenant ce dernier en tant que principe actif |
WO2017049177A1 (fr) * | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Agonistes du récepteur x farnésoïde et leurs utilisations |
US10626081B2 (en) | 2015-09-16 | 2020-04-21 | Metacrine, Inc. | Farnesoid X receptor agonists and uses thereof |
WO2017049173A1 (fr) | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Agonistes du récepteur x farnésoïde et leurs utilisations |
WO2017049176A1 (fr) * | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Agonistes du récepteur x farnésoïde et leurs utilisations |
CN105477636B (zh) * | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
CN107126419B (zh) | 2016-02-26 | 2020-06-19 | 石药集团中诺药业(石家庄)有限公司 | 一种奥贝胆酸片剂及其制备方法 |
WO2017170182A1 (fr) | 2016-03-31 | 2017-10-05 | 株式会社Adeka | Composition photosensible et nouveau composé |
JP7258763B2 (ja) | 2017-03-15 | 2023-04-17 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
JP7174709B2 (ja) | 2017-03-15 | 2022-11-17 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
US20200131142A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
US20200131132A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
US20200131129A1 (en) | 2017-03-15 | 2020-04-30 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
CZ2017298A3 (cs) | 2017-05-26 | 2018-12-05 | Zentiva, K.S. | Amorfní formy obeticholové kyseliny |
WO2020060007A1 (fr) | 2018-09-17 | 2020-03-26 | 엘지전자 주식회사 | Procédé et dispositif sans fil pour gérer une session de pdu dans une communication mobile 5g |
MX2021003083A (es) | 2018-09-18 | 2021-05-27 | Metacrine Inc | Formas cristalinas de un agonista del receptor de farnesoide x. |
CN113056266A (zh) | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 用于治疗疾病的法尼醇x受体激动剂 |
WO2020061116A1 (fr) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Agonistes du récepteur farnésoïde x et leurs utilisations |
JP2022500392A (ja) | 2018-09-18 | 2022-01-04 | メタクリン,インク. | ファルネソイドx受容体アゴニストおよびその使用 |
CN113056264A (zh) | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 法尼醇x受体激动剂及其用途 |
WO2020061118A1 (fr) | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Agonistes du récepteur farnésoïde x et leurs utilisations |
CN113056265A (zh) | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 法尼醇x受体激动剂及其用途 |
WO2021188692A1 (fr) | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formes cristallines d'un agoniste du récepteur farnésoïde x |
AU2021240001A1 (en) | 2020-03-18 | 2022-10-13 | Organovo, Inc. | Farnesoid X receptor agonists for the treatment of disease |
EP4121012A1 (fr) | 2020-03-18 | 2023-01-25 | Metacrine, Inc. | Formulations d'un agoniste du récepteur farnésoïde x |
-
2019
- 2019-09-17 JP JP2021513407A patent/JP2022500392A/ja active Pending
- 2019-09-17 KR KR1020217011359A patent/KR20210076910A/ko unknown
- 2019-09-17 WO PCT/US2019/051603 patent/WO2020061113A1/fr unknown
- 2019-09-17 AU AU2019344903A patent/AU2019344903A1/en active Pending
- 2019-09-17 MX MX2021003110A patent/MX2021003110A/es unknown
- 2019-09-17 CN CN201980075902.2A patent/CN113056271A/zh active Pending
- 2019-09-17 MA MA053665A patent/MA53665A/fr unknown
- 2019-09-17 US US16/573,993 patent/US11084817B2/en active Active
- 2019-09-17 CA CA3112411A patent/CA3112411A1/fr active Pending
- 2019-09-17 SG SG11202102651SA patent/SG11202102651SA/en unknown
- 2019-09-17 BR BR112021004919-3A patent/BR112021004919A2/pt unknown
- 2019-09-17 EP EP19862391.0A patent/EP3852748A4/fr active Pending
-
2021
- 2021-03-14 IL IL281475A patent/IL281475A/en unknown
- 2021-03-16 CL CL2021000632A patent/CL2021000632A1/es unknown
- 2021-03-17 PH PH12021550605A patent/PH12021550605A1/en unknown
- 2021-06-16 US US17/349,757 patent/US11773094B2/en active Active
-
2023
- 2023-07-17 US US18/353,659 patent/US20230382913A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA3112411A1 (fr) | 2020-03-26 |
MX2021003110A (es) | 2021-05-13 |
KR20210076910A (ko) | 2021-06-24 |
EP3852748A1 (fr) | 2021-07-28 |
WO2020061113A1 (fr) | 2020-03-26 |
IL281475A (en) | 2021-04-29 |
BR112021004919A2 (pt) | 2021-06-01 |
CL2021000632A1 (es) | 2021-07-23 |
US20230382913A1 (en) | 2023-11-30 |
PH12021550605A1 (en) | 2021-10-04 |
JP2022500392A (ja) | 2022-01-04 |
SG11202102651SA (en) | 2021-04-29 |
US20210395253A1 (en) | 2021-12-23 |
EP3852748A4 (fr) | 2022-05-18 |
TW202024052A (zh) | 2020-07-01 |
US20200102308A1 (en) | 2020-04-02 |
US11084817B2 (en) | 2021-08-10 |
AU2019344903A1 (en) | 2021-05-13 |
CN113056271A (zh) | 2021-06-29 |
US11773094B2 (en) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53665A (fr) | Agonistes du récepteur farnésoïde x et leurs utilisations | |
MA56480A (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
MA54555A (fr) | Agonistes de glp-1r et leurs utilisations | |
MA55627A (fr) | Agonistes de glp-1r et leurs utilisations | |
DK3350165T3 (da) | Farnesoid-X-receptoragonister og anvendelser deraf | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA50502A (fr) | Adénovirus et utilisations associées | |
MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
MA52414A (fr) | Anticorps agonistes de pd-1 et leurs utilisations | |
MA43417A (fr) | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations | |
DK3596053T3 (da) | Farnesoid-x-receptoragonister og anvendelser deraf | |
DK3383916T3 (da) | Anti-CD73-antistoffer og anvendelser deraf | |
MA49687A (fr) | Anticorps anti-ctla-4 et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA49683A (fr) | Anticorps anti-cd8 et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
DK3443009T3 (da) | Anti-tim-3-antistoffer og sammensætninger | |
MA52949A (fr) | Anticorps anti-pd-1 et leurs utilisations | |
MA52773A (fr) | Anticorps anti-cd3 et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
MA49886A (fr) | Anticorps anti-par2 et leurs utilisations | |
MA46540A (fr) | Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations |